Abstract
For effective tumour imaging by magnetic resonance imaging (MRI) there is a clear need to develop organ, tissue and cell specific contrast agents that can selectively bind to tumour biomarkers. The versatility of a range of bioconjugation techniques and facile coupling chemistries has facilitated the synthesis of MRI contrast agents bearing tumour targeting moieties that comprise small molecule affinity ligands, peptides, antibodies and even proteins. The aim of this review is to describe the development and implementation of tumour targeted T1 MRI contrast agents, with an emphasis on the chemistry used to modify pre-existing clinical MRI contrast agents for targeted tumour imaging.
Keywords: MRI, MRI contrast agents, Gadolinium, Cancer, Tumour, Tumour targeting, T1 contrast agents, Nanoparticles, Nanomedicine, Paramagnetic contrast agents
Current Topics in Medicinal Chemistry
Title: Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Volume: 10 Issue: 12
Author(s): Nazila Kamaly, Andrew D. Miller and Jimmy D. Bell
Affiliation:
Keywords: MRI, MRI contrast agents, Gadolinium, Cancer, Tumour, Tumour targeting, T1 contrast agents, Nanoparticles, Nanomedicine, Paramagnetic contrast agents
Abstract: For effective tumour imaging by magnetic resonance imaging (MRI) there is a clear need to develop organ, tissue and cell specific contrast agents that can selectively bind to tumour biomarkers. The versatility of a range of bioconjugation techniques and facile coupling chemistries has facilitated the synthesis of MRI contrast agents bearing tumour targeting moieties that comprise small molecule affinity ligands, peptides, antibodies and even proteins. The aim of this review is to describe the development and implementation of tumour targeted T1 MRI contrast agents, with an emphasis on the chemistry used to modify pre-existing clinical MRI contrast agents for targeted tumour imaging.
Export Options
About this article
Cite this article as:
Kamaly Nazila, D. Miller Andrew and D. Bell Jimmy, Chemistry of Tumour Targeted T1 Based MRI Contrast Agents, Current Topics in Medicinal Chemistry 2010; 10 (12) . https://dx.doi.org/10.2174/156802610791384199
DOI https://dx.doi.org/10.2174/156802610791384199 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Exploration of Chemical Space Based on 4-Anilinoquinazoline
Current Medicinal Chemistry Nanoparticle-Derived Non-Viral Genetic Transfection at the Blood-Brain Barrier to Enable Neuronal Growth Factor Delivery by Secretion from Brain Endothelium
Current Medicinal Chemistry New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Recovery of Locomotor Function with Combinatory Drug Treatments Designed to Synergistically Activate Specific Neuronal Networks
Current Medicinal Chemistry L-Thyroxine Acts as a Hormone as well as a Prohormone at the Cell Membrane
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design A Simple, Efficient and Environmentally Benign Synthetic Protocol for the Synthesis of Spirooxindoles Using Choline Chloride-Oxalic Acid Eutectic Mixture as Catalyst/Solvent System
Combinatorial Chemistry & High Throughput Screening Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Cellular and Molecular Regulation of Inflammatory Pain, Nociception and Hyperalgesia - The Role of the Transcription Factor NF-κB as the Lynchpin Nocisensor: Hyperalgesic or Analgesic Effect?
Current Immunology Reviews (Discontinued) Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis
Current Pharmaceutical Design MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine